sorafenib has been researched along with cgp 57380 in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cgp 57380) | Trials (cgp 57380) | Recent Studies (post-2010) (cgp 57380) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 64 | 0 | 44 |
| Protein | Taxonomy | sorafenib (IC50) | cgp 57380 (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase Sgk1 | Homo sapiens (human) | 2.7 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 3 | Homo sapiens (human) | 3.2 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 1.6 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 2.5 | |
| Eukaryotic translation initiation factor 4E | Homo sapiens (human) | 3 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.6 | |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | 5 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.51 | |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | 1.1 | |
| Aurora kinase B | Homo sapiens (human) | 2.5 | |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 1.2182 | |
| MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 2.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Guan, L; Huang, M; Li, B; Li, D; Liu, B; Liu, D; Wang, S; Zang, J; Zhao, L | 1 |
2 other study(ies) available for sorafenib and cgp 57380
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
Topics: Amides; Antineoplastic Agents; Benzofurans; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Intracellular Signaling Peptides and Proteins; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Structure-Activity Relationship | 2018 |